We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-22.93%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$281M
AUM Growth
-$90.3M
Cap. Flow
-$1.02M
Cap. Flow %
-0.36%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$1.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.87B
$255M 90.72%
1,753,528
– –
NVAX icon
2
Novavax
NVAX
$1.23B
$14M 4.96%
67,373
– –
XLRN
3
DELISTED
Acceleron Pharma
XLRN
$7.9M 2.81%
45,884
– –
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$4.26M 1.51%
832,336
-167,666
-17% -$1.02M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2021 Portfolio in Review

As of Q3 2021, Foresite Capital Management II held 4 positions worth $281M, down 24% from $372M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 0%. Foresite Capital Management II opened no new positions and made no exits, leaving the 4-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management II's biggest Q3 2021 reduction was Epizyme, Inc, cutting an estimated $1.02M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $281M portfolio in Q3 2021.
  • Foresite Capital Management II opened 0 new positions and closed 0 in Q3 2021.
  • Foresite Capital Management II's portfolio value fell 24% quarter-over-quarter to $281M.

Based on Foresite Capital Management II's 13F filing for Q3 2021, filed 12 Nov 2021.